Clinical Trial Update: Levocetirizine 5 mg: Reduction of Symptoms, Airway Resistance and Sleep Impairment in Persistent Allergic Rhinitis [Phase 4]

View source ↗

Summary

Phase 4 clinical trial of Levocetirizine 5 mg demonstrated reductions in allergic rhinitis symptoms, airway resistance, and sleep impairment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• Levocetirizine (Levocetirizine)

Snippet

Sponsor: Institut für Atemwegsforschung GmbH | Conditions: Allergic Rhinitis | Phase 4 | Status: COMPLETED